RE: What will the Groome report say?BarryLyndon,
1) No capability of in-house research - IMM made it clear already that it plans to be a biotech merchant developer. That is acquire drugs that have good/excellent prospects & develop them. IMM has a global network of scientific experts to guide them in determining if a drug has good potentials & can be brought into the commercialization phase. There can be many kinds of research - in the lab, paperwork, sourcing, discussion, etc. It is just apparent that lab is not a major part of IMM's research program cos' potential drugs are usually acquired at the pre-clinical phase.
2) ROB interviews in my opinion is simply a joke at times. Why? Because the interviewers judge companies by size at most times & underestimate them. As for that interview, Michael is simply a pain in the butt. I'm quite shocked that IMM could actually tolerate throughout the interview.
3) BCR acquistion provides not just the intellengent personnel but also the lab facilities (strong infrastructure) & revenues (financial stability). What u fail to realize is that BCR is just an incubator for biotechs ie providing the tools necessary for biotech start-ups. Who mentioned that IMM would have claims on any of the "incubated " intellectual properties of other companies?
4) Financing should be able to provide for Dapsone's clinical studies. IMM has a limit of 100 million authorized shares & they had only used 30 million share. Do u know that drugs for Alzheimer's Disease are worth over a billion dollar market? The current two drugs for treating AD have severe side-effects compared to Dapsone. As a note, Dapsone is out in the market for decades. IMM's AD drug is one of the most advanced if not the most advanced clinical testing phase currently. This could put IMM's AD drug with a fast-track status from the regulatory authorities. With a fast-track staus, government will review the drug within 6 months instead of the norm 12-18 months. Furthermore with the medical & economic burden of AD on countries, AD has became a hot topic in this industry.
From my point of view, U are just simply ignorant. Why don't u just wait for Groome Report to be out before u bash on IMM. If the report comes out to be good (in which I would think so cos' no brokerages would want to cover on lousy stocks), I wonder if u will still change your tune. I think u must be waiting to jump into IMM stocks just want to purchase them at a much much cheaper price by bashing on IMM. If u are not interested in IMM, why do u want to spend the effort of writing on the bullboard just get out of the forum.